Stockreport

Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial [Canadian Business Journal (Canada)]

Psyence Biomedical Ltd. - Ordinary Shares  (PBM) 
PDF NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derive [Read more]